Back to Authors

Sivak, Erica L.

https://orcid.org/0000-0001-9308-6082

Mayo Clinic

University of Pittsburgh

Citations 1

Exome analysis identifies Brody myopathy in a family diagnosed with malignant hyperthermia susceptibility
Sambuughin, Nyamkhishig , Zvaritch, Elena, Kraeva, Natasha , Sizova, Olga , Sivak, Erica L. , Dickson, Kelley M, Weglinski, Margaret R., Capacchione, John F., Muldoon, Sheila M., Brandom, Barbara W., MacLennan, David H. , Weglinski, Margaret, Riazi, Sheila , Hamilton, Susan L.

Molecular Genetics & Genomic Medicine | June 6, 2014 | Volume: 2 | Issue: 6 | Pages: 472-483

10.1002/mgg3.91 Get It

AbstractWhole exome sequencing (WES) was used to determine the primary cause of muscle disorder in a family diagnosed with a mild, undetermined myopathy and malignant hyperthermia (MH) susceptibility (MHS). WES revealed the compound heterozygous mutations, p.Ile235Asn and p.Glu982Lys, in ATP2A1, encoding the sarco(endo)plasmic reticulum Ca2+ ATPase type 1 (SERCA1), a calcium pump, expressed in fast‐twitch muscles. Recessive mutations in ATP2A1 are known to cause Brody myopathy, a rare muscle disorder characterized by exercise‐induced impairment of muscle relaxation and stiffness. Analyses of affected muscles showed the absence of SERCA1, but SERCA2 upregulation in slow and fast myofibers, suggesting a compensatory mechanism that partially restores the diminished Ca2+ transport in Brody myopathy. This compensatory adaptation to the lack of SERCA1 Ca2+ pumping activity within the muscle explains, in part, the mild course of disease in our patient. Diagnosis of MHS in this family was secondary to a loss of SERCA1 due to disease‐associated mutations. Although there are obvious differences in clinical expression and molecular mechanisms between MH and Brody myopathy, a feature common to both conditions is elevated myoplasmic Ca2+ content. Prolonged intracellular Ca2+ elevation is likely to have led to MHS diagnosis in vitro and postoperative MH‐like symptoms in Brody patient.